LamdaGen Corporation Accelerates Development of its HS-CRP (High Sensitivity C-Reactive Protein) Point of Care Test for Specific Use in the Early Prediction of Heart Attack and Stroke

LamdaGen Corporation, Menlo Park, California, announced today that its scientific team has entered into its second phase of development for the Company’s Point of Care diagnostic assay for CRP. Earlier this year LamdaGen presented important CRP data at the prestigious AACC Oakridge Conference, evidencing its technology’s ability to achieve rapid, highly-sensitivity results for CRP in minutes with only a few drops of whole blood.

Cardiovascular disease is the No. 1 cause of pain, suffering and death in both Men and Women in the U.S. And half of all heart attacks occur in people with normal or low cholesterol, so doctors have been testing other ways to predict who is at risk.

Sunday, at an American Heart Association conference in New Orleans, an important study, hailed as a watershed event in heart disease prevention, indicated high levels of CRP, which indicates inflammation in the body, can be used as a prime indicator of potential future cardiac disease.

W. Douglas Weaver, president of the American College of Cardiology, was quoted as saying "This study takes prevention to a whole new level because it applies to patients who we now wouldn't have any evidence to treat."

LamdaGen’s CRP assay is based upon the Company’s patented nano-based E-LSPR (enhanced surface plasmon resonance) technology which provides highly-sensitive and on the spot quantification of CRP levels in whole blood or serum in minutes.